MX2023010909A - Derivados de purina como agentes anticancerigenos. - Google Patents

Derivados de purina como agentes anticancerigenos.

Info

Publication number
MX2023010909A
MX2023010909A MX2023010909A MX2023010909A MX2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A MX 2023010909 A MX2023010909 A MX 2023010909A
Authority
MX
Mexico
Prior art keywords
sup
anticancer agents
purine derivatives
formula
ring
Prior art date
Application number
MX2023010909A
Other languages
English (en)
Spanish (es)
Inventor
Scott Throner
Daniel Jönsson
Original Assignee
Tango Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tango Therapeutics Inc filed Critical Tango Therapeutics Inc
Publication of MX2023010909A publication Critical patent/MX2023010909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023010909A 2021-03-17 2022-03-17 Derivados de purina como agentes anticancerigenos. MX2023010909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
MX2023010909A true MX2023010909A (es) 2024-02-13

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010909A MX2023010909A (es) 2021-03-17 2022-03-17 Derivados de purina como agentes anticancerigenos.

Country Status (11)

Country Link
US (1) US20240059689A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511996A (cg-RX-API-DMAC7.html)
KR (1) KR20240006509A (cg-RX-API-DMAC7.html)
CN (1) CN117425656A (cg-RX-API-DMAC7.html)
AU (1) AU2022238886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212292A1 (cg-RX-API-DMAC7.html)
IL (1) IL305991A (cg-RX-API-DMAC7.html)
MX (1) MX2023010909A (cg-RX-API-DMAC7.html)
WO (1) WO2022197892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240190A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
EP4739397A1 (en) 2023-07-06 2026-05-13 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
AU2024378865A1 (en) 2023-11-10 2026-06-25 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-(氟磺酰基)氨基甲酸酯化合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406129T3 (es) * 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Also Published As

Publication number Publication date
US20240059689A1 (en) 2024-02-22
BR112023018799A2 (pt) 2023-12-12
IL305991A (en) 2023-11-01
CN117425656A (zh) 2024-01-19
AU2022238886A1 (en) 2023-09-14
EP4308566A1 (en) 2024-01-24
KR20240006509A (ko) 2024-01-15
CA3212292A1 (en) 2022-09-22
JP2024511996A (ja) 2024-03-18
WO2022197892A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2023014620A (es) Nuevos profarmacos y conjugados de dimetiltriptamina.
MX2024000299A (es) Compuestos antivirales.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2024009177A (es) Compuestos y metodos de uso
EP4252848A3 (en) Oxysterols and methods of use thereof
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12022550175A1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
WO2022115381A8 (en) Compositions and methods for treating cns disorders
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
MX2025005846A (es) Compuestos moduladores de nmda negativos y métodos de uso de estos.
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
MX2024003645A (es) Derivados de piridinilacetamida como activadores de canales de sodio.
UY27577A1 (es) Inhibidores de la integrasa del vih
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
MX2022007518A (es) Derivados bencimidazol.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2025010952A (es) Derivados de amida para inhibir el gen nlrp3 y usos de los mismos
MX2025008428A (es) Derivados de piperidina como inhibidores de mettl3
MX2024003647A (es) Derivados de piridina y su uso como activadores del canal de sodio.
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)